Compare STRT & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STRT | AVXL |
|---|---|---|
| Founded | 1908 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 344.3M | 397.6M |
| IPO Year | 1995 | N/A |
| Metric | STRT | AVXL |
|---|---|---|
| Price | $77.87 | $4.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $22.00 |
| AVG Volume (30 Days) | 47.2K | ★ 1.6M |
| Earning Date | 02-05-2026 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 45.55 | N/A |
| EPS | ★ 5.73 | N/A |
| Revenue | ★ $578,413,000.00 | N/A |
| Revenue This Year | $4.15 | N/A |
| Revenue Next Year | $4.12 | N/A |
| P/E Ratio | $13.61 | ★ N/A |
| Revenue Growth | ★ 6.83 | N/A |
| 52 Week Low | $31.57 | $2.86 |
| 52 Week High | $86.47 | $13.99 |
| Indicator | STRT | AVXL |
|---|---|---|
| Relative Strength Index (RSI) | 51.58 | 57.76 |
| Support Level | $78.41 | $4.67 |
| Resistance Level | $80.39 | $5.36 |
| Average True Range (ATR) | 3.34 | 0.29 |
| MACD | -0.38 | 0.04 |
| Stochastic Oscillator | 37.86 | 65.08 |
Strattec Security Corp designs develops, manufactures, and markets mechanical locks, electronically enhanced locks, and keys. It also produces ignition lock housings; and access control products, including latches, power sliding door systems, and door handles. Strattec ships products to customer locations in the United States, Canada, Mexico, Europe, South America, Korea, and China, and provides full-service aftermarket support. Strattec also supplies products for the heavy truck and recreational vehicle markets, as well as precision, die castings.
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.